Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study

INTRODUCTION: Upadacitinib, an oral, selective Janus kinase inhibitor, is approved in Japan for the treatment of moderate-to-severe atopic dermatitis (AD), a chronic inflammatory skin disease characterized by eczematous morphology and intense itch. METHODS: Rising Up is an ongoing phase 3, randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Katoh, Norito, Ohya, Yukihiro, Murota, Hiroyuki, Ikeda, Masanori, Hu, Xiaofei, Ikeda, Kimitoshi, Liu, John, Sasaki, Takuya, Raymundo, Eliza M., Teixeira, Henrique D., Saeki, Hidehisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823168/
https://www.ncbi.nlm.nih.gov/pubmed/36401761
http://dx.doi.org/10.1007/s13555-022-00842-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823168/
https://www.ncbi.nlm.nih.gov/pubmed/36401761
http://dx.doi.org/10.1007/s13555-022-00842-7

Ejemplares similares